Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA known ✓ | P35790 | 1/20 | 0.43 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907268 | 0.89 | CHKA (0.44) | CHKACHRM3 | |
| Bromide SCHEMBL2818241 | 0.84 | CHKA (0.44) | CHKACHRM3 | |
| SCHEMBL4903168 | 0.82 | CHKA (0.42) | CHKACHRM3 | |
| SCHEMBL4906507 | 0.82 | CHKA (0.42) | CHKA | |
| SCHEMBL4546743 | 0.70 | CHKA (0.41) | CHKACHRM3 | |
| Bromide SCHEMBL2816500 | 0.69 | APOBEC3A (0.46) | CHKACHRM3 | |
| SCHEMBL4903052 | 0.68 | CHKA (0.42) | CHKA | |
| Iodide SCHEMBL30832965 | 0.68 | RGS12 (0.36) | CHRM3 | |
| SCHEMBL20663048 | 0.66 | CHKA (0.35) | CHKACHRM3 | |
| SCHEMBL4896775 | 0.62 | KDM4E (0.40) | CHKACHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249420-A9 | Process for preparing quinuclidinium carbamate derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| US-20090198064-A1 | Process for preparing quinuclidinium carbamate derivatives | LABORATORIOS ALMIRALL S.A. (ES) | 2009-08-06 | — | — | US | disclosed |
| EP-1781651-B1 | PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES | ALMIRALL LAB (ES) | 2009-03-11 | — | — | EP | disclosed |
| EP-1781651-A1 | PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006010452-A1 | PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249420-A9 | Process for preparing quinuclidinium carbamate derivatives | CPS1, NAAA, QPCT | CHKA 423/4885CHRM3 549/4885 |
| US-20090198064-A1 | Process for preparing quinuclidinium carbamate derivatives | CPS1, NAAA, QPCT | CHKA 423/4885CHRM3 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.